StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.06−0.44 (-12.57%)

Close on Nov 18, 2026Market cap $62.83KP/E –Yield –

Addex Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was CHF 671.65K, down 21.4% from the year before. The highest annual figure on record is CHF 12.84M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 671.65K-21.4%
FY2024Dec 31, 2024CHF 854.31K-28.0%
FY2023Dec 31, 2023CHF 1.19M-85.6%
FY2022Dec 31, 2022CHF 8.24M-35.8%
FY2021Dec 31, 2021CHF 12.84M+23.8%
FY2020Dec 31, 2020CHF 10.37M-16.7%
FY2019Dec 31, 2019CHF 12.45M+153.2%
FY2018Dec 31, 2018CHF 4.92M+87.1%
FY2017Dec 31, 2017CHF 2.63M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026CHF 37.99K-99.3%
Q2 FY2025Jun 30, 2025CHF 234.45K-93.7%
Q2 FY2024Jun 30, 2024CHF 339.32K–
Q2 FY2023Jun 30, 2023CHF 1.88M–
Q2 FY2022Jun 30, 2022CHF 5.75M–
Q2 FY2021Jun 30, 2021CHF 3.73M–

More Addex Therapeutics figures

See a number that looks wrong?